A Randomized Phase II Study of Sequential Biotherapy With Aflibercept and High Dose IL-2 Versus High Dose IL-2 Alone in Patients With Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study
This randomized phase II clinical trial studies how well aldesleukin with or without
ziv-aflibercept works in treating patients with stage III-IV melanoma that cannot be removed
by surgery. Aldesleukin may stimulate the white blood cells to kill cancer. Ziv-aflibercept
may stop the growth of melanoma by blocking blood flow to the tumor. It is not yet known
whether aldesleukin is more effective with or without ziv-aflibercept in treating melanoma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.